Holds an Economics degree by Universidad del Pacifico in Lima, Peru. In addition, professor Mould-Quevedo completed a Master in Economics in Mexico at Centro de Investigación y Docencia Económicas (CIDE) and a Master in Business Administration at Paris University (Sorbonne Business School) in France. Also, holds a PhD in Applied Economics given by Universidad de Alicante in Spain. In addition, he has developed advanced courses of pharmacoeconomics at York University in United Kingdom.
Regarding his professional experience, Dr. Mould occupied Director positions in Health Economics and Market Access for Pfizer Inc., Bayer Healthcare and Seqirus USA Inc. He had performed over 200 Pharmacoeconomics & Outcomes Research assessments; over 70 publications of Health Economics and Outcomes Research topics in international peer-review journals and over 175 presentations at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meetings. He had also been a manuscript reviewer for Value in Health, Pharmacoeconomics, Pan American Journal of Public Health and Vaccines Journal. Previous to his career in the pharmaceutical industry, he worked in the Social Security Mexican Institute as Health Economics Researcher for two years (2003-2005) and he also was the President for 2012-2014 Health Technology Producers (Industry) Committee at the Latin American ISPOR Consortium.
A Real-World Comparison between Adjuvanted Trivalent Influenza Vaccine and Trivalent High-Dose Influenza Vaccine for the 2019–20 Season
Joaquin Mould-Quevedo, Seqirus USA Inc., United States
Immunosenescence, an age-related decline in immune function, results in suboptimal immune responses to influenza vaccines. There is also considerable vaccine effectiveness heterogeneity depending on the influenza activity time period, especially in seasons in which different circulating strains predominated, such as the 2019–20 season. This research aimed to assess the effect of high influenza activity period (HIAP) and age on the relative vaccine effectiveness (rVE) of adjuvanted trivalent influenza vaccine (aTIV) versus high-dose trivalent influenza vaccine (HD-TIV) among older adults (≥65 years old) recipients in the United States.
During the 2019–20 influenza season, a retrospective cohort analysis was conducted using IQVIA’s professional fee, prescription claims, and hospital charge master data in the United States. The first sub-analysis evaluated rVE for different age groups (65–74 years, 75–84 years, ≥85 years) with an observation period from Aug 1, 2019–Mar 7, 2020, ending early to avoid any influenza outcome misclassification with coronavirus disease 2019 (COVID-19) infection. The second sub-analysis evaluated rVE overall, restricting the observation period to HIAP: Dec 8, 2019–Mar 7, 2020. Adjusted analyses were conducted through inverse probability of treatment weighting (IPTW) to control for selection bias. Poisson regression was used to estimate the adjusted pairwise rVE for influenza-related hospitalizations/emergency room (ER) visits.
Following IPTW, 798,987 recipients of aTIV and 1,655,979 of HD-TIV were identified. Following IPTW adjustment and Poisson regression, aTIV was comparable in reducing influenza-related hospitalizations/ER visits compared with HD-TIV (3.6%; 95% confidence interval [CI]: −2.4–9.3) in the HIAP sub-analysis. In the age sub-analysis, the rVE for aTIV ranged from 4.5% (95% CI: −4.0–12.4) for the youngest group (65–74 years old) up to −8.8% (95% CI: −25.0–5.3) for the eldest group (≥85 years old) for influenza-related hospitalizations/ER visits.
In adjusted analyses, aTIV and HD-TIV demonstrated comparable reductions in influenza-related hospitalizations/ER visits by age group and during HIAP among older adults during the 2019–20 season.
Seqirus USA Inc.